ad image

AML

1 / 1
Moleculin Biotech, Inc.
AML

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Biotech, Inc.

PR-11-24-NI-102Nov 15, 2024
Actinium Pharmaceuticals, Inc.
COVID-19 Test

100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc.

PR-M11-20-003Nov 04, 2020
1 / 1